UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 26

Sortiert nach

Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial

Cancer discovery, 2019-04, Vol.9 (4), p.510-525

2019

Volltextzugriff (PDF)

Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study

The lancet oncology, 2020-02, Vol.21 (2), p.283-293

2020

Volltextzugriff (PDF)

Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study

The lancet oncology, 2018-12, Vol.19 (12), p.1688-1698

2018

Volltextzugriff (PDF)

EPIK-B4: A phase 2, randomized study of metformin (MET) extended release (XR) +/- dapagliflozin (DAPA) to prevent hyperglycemia (HG) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA -mutated (mut) advanced breast cancer (ABC) treated with alpelisib (ALP) and fulvestrant (FUL)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS1107-TPS1107

2022

Volltextzugriff (PDF)

Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms

Endocrine-related cancer, 2021-03, Vol.28 (3), p.161-172

2021

Volltextzugriff (PDF)

EPIK-B5: A phase III, randomized study of alpelisib (ALP) plus fulvestrant (FUL) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA -mutated advanced breast cancer (ABC) progressing on/after an aromatase inhibitor (AI) with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS1109-TPS1109

2022

Volltextzugriff (PDF)

Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Biomarker (BM) analyses by next-generation sequencing (NGS) from the SOLAR-1 study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.1006-1006

2022

Volltextzugriff (PDF)

PTEN Expression, Not Mutation Status in TSC1, TSC2 , or mTOR , Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial

Clinical cancer research, 2019-01, Vol.25 (2), p.506-514

2019

Volltextzugriff (PDF)

Immune infiltration and angiogenesis as markers of outcome in the post-nephrectomy setting: Transcriptomic data from patients receiving placebo on a randomized phase III trial (PROTECT)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.5082-5082

2020

Volltextzugriff (PDF)

PD49-01 THERAPY-RELEVANT GENE SIGNATURES IN THE HIGH RISK LOCALIZED RENAL CELL CARCINOMA SETTING: TRANSCRIPTOMIC DATA FROM PATIENTS RECEIVING PLACEBO ON A RANDOMIZED PHASE 3 TRIAL (PROTECT)

The Journal of urology, 2021-09, Vol.206 (Supplement 3)

2021

Volltextzugriff (PDF)

Therapy-relevant gene signatures in the high risk localized renal cell carcinoma setting: Transcriptomic data from patients receiving placebo on a randomized phase III trial (PROTECT)

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.353-353

2021

Volltextzugriff (PDF)

Abstract PD2-06: Clinical outcomes of alpelisib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer with PIK3CA alterations detected in plasma ctDNA by next-generation sequencing: Biomarker analysis from the SOLAR-1 study

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PD2-06-PD2-06

2021

Volltextzugriff (PDF)

A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma

Clinical genitourinary cancer, 2021-10, Vol.19 (5), p.434-446

2021

Volltextzugriff (PDF)

Abstract P4-10-04: Clinical outcomes of alpelisib in hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer by next-generation sequencing-detected PIK3CA alteration status and phosphatase and tensin homolog loss: Biomarker analysis from the SOLAR-1 study

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P4-P4-10-04

2020

Volltextzugriff (PDF)

Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a retrospective cohort study

The lancet oncology, 2019-12, Vol.21 (2), p.283-293

2019

Volltextzugriff (PDF)

Characterizing tumor immune microenvironment (TME) and outcomes for 409 patients (pts) treated on COMPARZ: Distinct clusters emphasize immune infiltration vs. angiogenesis

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.4515-4515

2018

Volltextzugriff (PDF)

Incorporation of PBRM1 , BAP1 , TP53 mutation status into the Memorial Sloan Kettering Cancer Center (MSKCC) risk model: A genomically annotated tool to improve stratification of patients (pts) with advanced renal cell carcinoma (RCC)

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.639-639

2018

Volltextzugriff (PDF)

Serum biomarkers of inflammation (ferritin, IL-8, TNFR1) and outcomes in BOLERO-2, a phase III trial of HR+/HER2- metastatic breast cancer treated with everolimus (mTOR inhibitor)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.1067-1067

2020

Volltextzugriff (PDF)

Modulation of Marrow Proliferation and Chemosensitivity by Tumor-produced Cytokines from Syngeneic Pancreatic Tumor Lines

Clinical cancer research, 2002-05, Vol.8 (5), p.1301-1309

2002

Volltextzugriff (PDF)

Abstract P5-02-32: Differential Gene Mutation Landscape in Patients With PIK3CA-altered and Non-altered Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer in the SOLAR-1 Clinical Study

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.P5-P5-02-32

2023

Volltextzugriff (PDF)

The use of rat lens explant cultures to study the mechanism of drug-induced cataractogenesis

Toxicological sciences, 2012-03, Vol.126 (1), p.128-139

2012

Volltextzugriff (PDF)

Anti‐oxidant vitamins reduce normal tissue toxicity induced by radio‐immunotherapy

International journal of cancer, 2000-04, Vol.86 (2), p.276-280

2000

Volltextzugriff (PDF)

The WISE 2000 and 2001 field experiments in support of the SMOS mission: sea surface L-band brightness temperature observations and their application to sea surface salinity retrieval

IEEE transactions on geoscience and remote sensing, 2004-04, Vol.42 (4), p.804-823

2004

Volltextzugriff (PDF)

Explaining Performance Trends in Leveraged Loan Investments

The Journal of fixed income, 2001-09, Vol.11 (2), p.83-94

2001

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(26)

Sprache

Englisch
(26)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(11)
Life Sciences & Biomedicine
(10)
Oncology
(9)
Humans
(6)
Male
(5)
Tumors
(5)
Animals
(4)
Carcinoma, Renal Cell - Genetics
(4)
Female
(4)
Kidney Neoplasms - Genetics
(4)
Aged
(3)
Carcinoma, Renal Cell - Mortality
(3)
Kidney Neoplasms - Mortality
(3)
Metastases
(3)
Metastasis
(3)
Mice
(3)
Middle Aged
(3)
Studies
(3)
Antineoplastic Agents - Therapeutic Use
(2)
Biological And Medical Sciences
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial

A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma

Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study

Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study

Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms

Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Biomarker (BM) analyses by next-generation sequencing (NGS) from the SOLAR-1 study

PTEN Expression, Not Mutation Status in TSC1, TSC2 , or mTOR , Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial

Immune infiltration and angiogenesis as markers of outcome in the post-nephrectomy setting: Transcriptomic data from patients receiving placebo on a randomized phase III trial (PROTECT)

PD49-01 THERAPY-RELEVANT GENE SIGNATURES IN THE HIGH RISK LOCALIZED RENAL CELL CARCINOMA SETTING: TRANSCRIPTOMIC DATA FROM PATIENTS RECEIVING PLACEBO ON A RANDOMIZED PHASE 3 TRIAL (PROTECT)

Therapy-relevant gene signatures in the high risk localized renal cell carcinoma setting: Transcriptomic data from patients receiving placebo on a randomized phase III trial (PROTECT)

Abstract PD2-06: Clinical outcomes of alpelisib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer with PIK3CA alterations detected in plasma ctDNA by next-generation sequencing: Biomarker analysis from the SOLAR-1 study

A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma

Abstract P4-10-04: Clinical outcomes of alpelisib in hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer by next-generation sequencing-detected PIK3CA alteration status and phosphatase and tensin homolog loss: Biomarker analysis from the SOLAR-1 study

Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a retrospective cohort study

Characterizing tumor immune microenvironment (TME) and outcomes for 409 patients (pts) treated on COMPARZ: Distinct clusters emphasize immune infiltration vs. angiogenesis

Incorporation of PBRM1 , BAP1 , TP53 mutation status into the Memorial Sloan Kettering Cancer Center (MSKCC) risk model: A genomically annotated tool to improve stratification of patients (pts) with advanced renal cell carcinoma (RCC)

Serum biomarkers of inflammation (ferritin, IL-8, TNFR1) and outcomes in BOLERO-2, a phase III trial of HR+/HER2- metastatic breast cancer treated with everolimus (mTOR inhibitor)

Modulation of Marrow Proliferation and Chemosensitivity by Tumor-produced Cytokines from Syngeneic Pancreatic Tumor Lines

Abstract P5-02-32: Differential Gene Mutation Landscape in Patients With PIK3CA-altered and Non-altered Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer in the SOLAR-1 Clinical Study

The use of rat lens explant cultures to study the mechanism of drug-induced cataractogenesis

Anti‐oxidant vitamins reduce normal tissue toxicity induced by radio‐immunotherapy

The WISE 2000 and 2001 field experiments in support of the SMOS mission: sea surface L-band brightness temperature observations and their application to sea surface salinity retrieval

Explaining Performance Trends in Leveraged Loan Investments

Suchergebnisse filtern